CA2271381A1 - Compositions et methodes pour traiter des troubles gastro-intestinaux - Google Patents

Compositions et methodes pour traiter des troubles gastro-intestinaux Download PDF

Info

Publication number
CA2271381A1
CA2271381A1 CA002271381A CA2271381A CA2271381A1 CA 2271381 A1 CA2271381 A1 CA 2271381A1 CA 002271381 A CA002271381 A CA 002271381A CA 2271381 A CA2271381 A CA 2271381A CA 2271381 A1 CA2271381 A1 CA 2271381A1
Authority
CA
Canada
Prior art keywords
bismuth
milligrams
composition
days
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002271381A
Other languages
English (en)
Inventor
Owen Rickford Carryl
Jonathan Davidson Kaunitz
Shin Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of CA2271381A1 publication Critical patent/CA2271381A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes et des compositions pour traiter les troubles gastro-intestinaux provoqués par Helicobacter pylori, contenant du bismuth et une quantité gastropathique d'un médicament anti-inflammatoire non stéroïdien. La composition peut également contenir une quantité suffisante pour avoir un effet thérapeutique, d'un ou de plusieurs médicaments anti-sécrétoires.
CA002271381A 1996-11-22 1997-11-21 Compositions et methodes pour traiter des troubles gastro-intestinaux Abandoned CA2271381A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75551796A 1996-11-22 1996-11-22
US08/755,517 1996-11-22
PCT/US1997/021462 WO1998022118A1 (fr) 1996-11-22 1997-11-21 Compositions et methodes pour traiter des troubles gastro-intestinaux

Publications (1)

Publication Number Publication Date
CA2271381A1 true CA2271381A1 (fr) 1998-05-28

Family

ID=25039481

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002271381A Abandoned CA2271381A1 (fr) 1996-11-22 1997-11-21 Compositions et methodes pour traiter des troubles gastro-intestinaux

Country Status (7)

Country Link
EP (1) EP0941102A1 (fr)
CN (1) CN1238694A (fr)
CA (1) CA2271381A1 (fr)
HU (1) HUP9904073A3 (fr)
NO (1) NO992468L (fr)
TR (1) TR199901101T2 (fr)
WO (1) WO1998022118A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
AU781133B2 (en) * 1999-02-26 2005-05-05 Nicox S.A. Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
TWI275587B (en) * 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US7285668B2 (en) * 2000-12-01 2007-10-23 Takeda Pharmaceutical Company Limited Process for the crystallization of (R)- or (S)-lansoprazole
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US6514960B1 (en) * 2001-08-27 2003-02-04 Hedonist Biochemical Technologies Co., Ltd. Use of bismuth subgallate in inhibition of production of nitric oxide synthase
US7211590B2 (en) 2002-08-01 2007-05-01 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
CA2570916C (fr) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Forme posologique d'ipp a doses multiples
KR101148399B1 (ko) * 2005-06-22 2012-05-23 일양약품주식회사 항궤양제 및 점막보호제를 함유하는 경구용 위장질환치료용 약제 조성물
JP2011513202A (ja) 2008-03-10 2011-04-28 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
CA2736547C (fr) 2008-09-09 2016-11-01 Pozen Inc. Procede d'administration d'une composition pharmaceutique a un patient en ayant besoin
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
MX2014007935A (es) 2011-12-28 2014-11-14 Pozen Inc Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico.
WO2023143573A1 (fr) * 2022-01-30 2023-08-03 上海石趣医药科技有限公司 Utilisation d'un composé contenant du bismuth dans un traitement de maladies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI910088A (fi) * 1990-01-09 1991-07-10 Gist Brocades Nv Oral farmaceutisk komposition.
US5128140A (en) * 1991-01-14 1992-07-07 The Procter & Gamble Company Swallowable pharmaceutical compositions
WO1993009784A1 (fr) * 1991-11-22 1993-05-27 The Procter & Gamble Company Preparation pharmaceutique de doses unitaires de subsalicylate de bismuth
ES2130152T3 (es) * 1991-12-06 1999-07-01 Glaxo Group Ltd Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.

Also Published As

Publication number Publication date
HUP9904073A3 (en) 2000-04-28
HUP9904073A2 (hu) 2000-03-28
WO1998022118A1 (fr) 1998-05-28
EP0941102A1 (fr) 1999-09-15
NO992468L (no) 1999-07-01
TR199901101T2 (xx) 1999-07-21
NO992468D0 (no) 1999-05-21
CN1238694A (zh) 1999-12-15

Similar Documents

Publication Publication Date Title
CA2271381A1 (fr) Compositions et methodes pour traiter des troubles gastro-intestinaux
WO1998022117A1 (fr) Compositions de traitement de troubles gastro-intestinaux contenant du bismuth, des anti-inflammatoires non steroidiens ainsi qu'un ou plusieurs agents anti-microbiens et methodes correspondantes
JP2648327B2 (ja) 胃腸疾患を治療するための組成物及び方法
Reimer Safety of long-term PPI therapy
Levi et al. Antral Helicobacter pylori, hypergastrinaemia, and duodenal ulcers: effect of eradicating the organism.
JP6366548B2 (ja) 胃酸分泌の即効性阻害剤
Quan et al. Sestrin2 prevents age-related intolerance to post myocardial infarction via AMPK/PGC-1α pathway
Lane et al. Recurrence of duodenal ulcer after medical treatment
Walker et al. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.
EP0206626B1 (fr) Utilisation de bismuth pour la fabrication d'un médicament destiné au traitement des désordres gastrointestinaux dûs à Campylobacter polyridis
JPS6248623A (ja) 胃腸疾患の治療のための医薬組成物
Salmon et al. Evaluation of colloidal bismuth (De-Nol) in the treatment of duodenal ulcer employing endoscopic selection and follow up
Cohen et al. Mechanism of aspirin injury to human gastroduodenal mucosa
Vergara et al. Helicobacter pylorieradication prevents recurrence from peptic ulcer haemorrhage
JP3288550B2 (ja) ヘリコバクター・ピロリ菌殺菌のための局所用口腔内投与剤
Kakinuma et al. Gastric mucosal blood flow and gastric secretion following intravenous administration of 5-fluorouracil in anesthetized rats
Akase et al. A comparative study of laboratory parameters and symptoms effected by Toki-shakuyaku-san and an iron preparation in rats with iron-deficiency anemia
Fraser et al. Effect of ranitidine bismuth citrate on postprandial plasma gastrin and pepsinogens.
Parente et al. Colloidal Bismuth Subcitrate and Ranitidne in the Short-Term Treatment of Benign Gastric Ulcer an Endoscopically Controlled Trial
CA2122478C (fr) Forme de dose unitaire du subsalicylate de bismuth
KR20100124054A (ko) 더덕 추출물 또는 더덕 사포닌을 포함하는 히스타민 분비 억제용 조성물
George et al. Peptic ulcer disease in children
SATO et al. The effects of a prostaglandin E1 analogue, misoprostol, on gastric mucosal blood volume index and haemoglobin oxygenation in humans
Britt Pedunculated islet-cell tumour of the duodenum
CN117919240A (zh) 一种治疗血管钙化的药物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued